@article{e4082c53b3074b5b92ae4e2f10fdaffb,
title = "2013 IDSA clinical practice guideline for vaccination of the immunocompromised host",
abstract = "An international panel of experts prepared an evidenced-based guideline for vaccination of immunocompromised adults and children. These guidelines are intended for use by primary care and subspecialty providers who care for immunocompromised patients. Evidence was often limited. Areas that warrant future investigation are highlighted.",
keywords = "asplenic patients, immunization, immunocompromised patients, immunodeficiency patients, immunosuppression, vaccination",
author = "Rubin, {Lorry G.} and Levin, {Myron J.} and Per Ljungman and Davies, {E. Graham} and Robin Avery and Marcie Tomblyn and Athos Bousvaros and Shireesha Dhanireddy and Lillian Sung and Harry Keyserling and Insoo Kang",
note = "Funding Information: Potential conflicts of interest. The following list is a reflection of what has been reported to the IDSA. In order to provide thorough transparency, the IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest is determined by a review process that includes assessment by the SPGC chair, the SPGC liaison to the development panel, the Board of Directors liaison to the SPGC, and, if necessary, the Conflict of Interest Task Force of the board. This assessment of disclosed relationships for possible conflict of interest is based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. R. A. has served as a subinvestigator on clinical trials funded by ViroPharma, Roche, and the CDC. A. B. has served as a subinves-tigator on clinical trials funded by Abbott, UCB, and Merck; served as a consultant to Dyax, Cubist, and Nutricia; received speaking fees from Merck; and received a writing honorarium from Up-To-Date, Inc. E. G. D. has served as a consultant with GlaxoSmithKline and received a grant from Pfizer. I. K. has received research funding from Amino Up Chemical. H. K. has received funding from Pfizer for a clinical trial. M. L. has served as a consultant for Merck, MedImmune, and GlaxoSmithKline; has received honoraria and patent license from Merck; is on an adjudication committee for GlaxoS-mithKline; and participates in research studies with Sanofi Pasteur, GlaxoS-mithKline, and Merck. P. L. has served as a consultant to ViroPharma, Vical, Clinigen, Astellas Pharma, and Pfizer; served as an investigator for ViroPhar-ma, Astellas Pharma, Pfizer, and Merck; and chaired a Data and Safety Monitoring Board for AiCuris. No conflicts: G. A., L. R., S. D., M. T., L. S., and E. W. All other authors report no potential conflicts.",
year = "2014",
month = feb,
doi = "10.1093/cid/cit684",
language = "English (US)",
volume = "58",
pages = "e44--e100",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",
}